Boston Partners Has $62.20 Million Stake in Zimmer Biomet Holdings, Inc. $ZBH

Boston Partners reduced its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 681,921 shares of the medical equipment provider’s stock after selling 7,956 shares during the period. Boston Partners owned approximately 0.34% of Zimmer Biomet worth $62,204,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Accent Capital Management LLC acquired a new position in shares of Zimmer Biomet in the 1st quarter valued at $35,000. Hilltop National Bank bought a new stake in Zimmer Biomet in the second quarter valued at about $42,000. True Wealth Design LLC increased its holdings in Zimmer Biomet by 875.0% in the second quarter. True Wealth Design LLC now owns 468 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 420 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in Zimmer Biomet in the first quarter valued at about $48,000. Finally, Brooklyn Investment Group boosted its holdings in Zimmer Biomet by 45.9% during the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock worth $52,000 after buying an additional 145 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.39% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of analyst reports. UBS Group cut their price target on shares of Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating on the stock in a research report on Thursday, November 6th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $100.00 target price (down previously from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. Stifel Nicolaus set a $110.00 price target on shares of Zimmer Biomet in a research report on Wednesday, November 5th. Redburn Partners set a $130.00 price objective on shares of Zimmer Biomet in a research report on Thursday, September 18th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $109.00.

Zimmer Biomet Price Performance

ZBH stock opened at $97.66 on Friday. The stock has a 50-day moving average price of $96.89 and a two-hundred day moving average price of $96.81. Zimmer Biomet Holdings, Inc. has a 1 year low of $85.33 and a 1 year high of $114.44. The stock has a market cap of $19.35 billion, a PE ratio of 23.76, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.88 by $0.02. The company had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.